Lazaros I Sakkas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6066239/publications.pdf

Version: 2024-02-01

109321 133252 4,182 131 35 59 citations h-index g-index papers 133 133 133 5204 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Delphinidin diminishes in vitro interferon- \hat{l}^3 and interleukin-17 producing cells in patients with psoriatic disease. Immunologic Research, 2022, 70, 161-173.	2.9	7
2	B regulatory cells in patients with autoimmune diseases: Pathogenic significance and therapeutic potential., 2022,, 37-53.		1
3	Immune checkpoint inhibitor-induced musculoskeletal manifestations. Rheumatology International, 2021, 41, 33-42.	3.0	32
4	Incidence, risk factors and validation of the RABBIT score for serious infections in a cohort of 1557 patients with rheumatoid arthritis. Rheumatology, 2021, 60, 2223-2230.	1.9	8
5	Heat Shock Proteins as Target Autoantigens in Autoimmune Rheumatic Diseases. Heat Shock Proteins, 2021, , 281.	0.2	O
6	Anti-Ro52 antibody is highly prevalent and a marker of better prognosis in patients with ovarian cancer. Clinica Chimica Acta, 2021, 521, 199-205.	1.1	14
7	Effect of Crocus sativus (Saffron) Intake on Top of Standard Treatment, on Disease Outcomes and Comorbidities in Patients with Rheumatic Diseases: Synthesis without Meta-Analysis (SWiM) and Level of Adherence to the CONSORT Statement for Randomized Controlled Trials Delivering Herbal Medicine Interventions, Nutrients, 2021, 13, 4274.	4.1	10
8	Tetracyclines Diminish In Vitro IFN-Î ³ and IL-17-Producing Adaptive and Innate Immune Cells in Multiple Sclerosis. Frontiers in Immunology, 2021, 12, 739186.	4.8	11
9	Major vault protein/lung resistance related protein: a novel biomarker for rheumatoid arthritis. Clinical and Experimental Rheumatology, 2021, 39, 1033-1042.	0.8	6
10	Treatment patterns and achievement of the treat-to-target goals in a real-life rheumatoid arthritis patient cohort: data from 1317 patients. Therapeutic Advances in Musculoskeletal Disease, 2020, 12, 1759720X2093713.	2.7	10
11	A study of antigen-specific anti-cytomegalovirus antibody reactivity in patients with systemic sclerosis and concomitant anti-Ro52 antibodies. Rheumatology International, 2020, 40, 1689-1699.	3.0	5
12	Adrenocorticotropic hormone: an effective "natural―biologic therapy for acute gout?. Rheumatology International, 2020, 40, 1941-1947.	3.0	7
13	Autoantibodies against specific nuclear antigens are present in psoriatic disease and are diminished by secukinumab. Clinica Chimica Acta, 2020, 510, 400-407.	1.1	9
14	Progressive multifocal leukoencephalopathy in a patient with systemic sclerosis treated with methotrexate: A case report and literature review. Journal of Scleroderma and Related Disorders, 2020, 5, NP1-NP6.	1.7	3
15	Curcumin mediates attenuation of pro-inflammatory interferon \hat{I}^3 and interleukin 17 cytokine responses in psoriatic disease, strengthening its role as a dietary immunosuppressant. Nutrition Research, 2020, 75, 95-108.	2.9	30
16	Antigen-specific humoral responses against Helicobacter pylori in patients with systemic sclerosis. Immunologic Research, 2020, 68, 39-47.	2.9	6
17	Primary Sjögren's Syndrome and Cardiovascular Disease. Current Vascular Pharmacology, 2020, 18, 447-454.	1.7	28
18	Kawasaki Disease and COVID-19. Mediterranean Journal of Rheumatology, 2020, 31, 268.	0.8	34

#	Article	IF	CITATIONS
19	Diagnostic and clinical significance of antigen-specific pancreatic antibodies in inflammatory bowel diseases: A meta-analysis. World Journal of Gastroenterology, 2020, 26, 246-265.	3.3	5
20	Systemic Sclerosis (Scleroderma). , 2020, , 263-275.		0
21	On the immunoregulatory role of statins in multiple sclerosis: the effects on Th17 cells. Immunologic Research, 2019, 67, 310-324.	2.9	19
22	A comprehensive analysis of antigen-specific antibody responses against human cytomegalovirus in patients with systemic sclerosis. Clinical Immunology, 2019, 207, 87-96.	3.2	20
23	Anti 1q antibodies in scleroderma. British Journal of Dermatology, 2019, 181, e17.	1.5	O
24	å¸åœ¨ä¼´æœ‰è,ºçº¤,°åŒ–的系统性硬化症æ,£è€…䏿£€æµ«å^°æŠ— C1q 自身抗体. British Jou	rnuatiof De	rmatology, 2
25	Targeting very early systemic sclerosis: a case-based review. Rheumatology International, 2019, 39, 1961-1970.	3.0	15
26	Mini Review: New Treatments in Psoriatic Arthritis. Focus on the IL-23/17 Axis. Frontiers in Pharmacology, 2019, 10, 872.	3.5	65
27	Apremilast increases IL-10-producing regulatory B cells and decreases proinflammatory T cells and innate cells in psoriatic arthritis and psoriasis. Rheumatology, 2019, 58, 2240-2250.	1.9	32
28	Anti 1q autoantibodies are frequently detected in patients with systemic sclerosis associated with pulmonary fibrosis. British Journal of Dermatology, 2019, 181, 138-146.	1.5	7
29	Platelets in Systemic Sclerosis: the Missing Link Connecting Vasculopathy, Autoimmunity, and Fibrosis?. Current Rheumatology Reports, 2019, 21, 15.	4.7	26
30	The Greek (Hellenic) rheumatology over the years: from ancient to modern times. Rheumatology International, 2019, 39, 947-955.	3.0	4
31	AB0678â€ANTIPROLIFERATIVE AND VASOACTIVE TREATMENT MODALITIES IN 457 CONSECUTIVE PATIENTS WI'S SYSTEMIC SCLEROSIS FROM ACADEMIC CENTERS IN GREECE., 2019,,.	TH	0
32	OP0015â€INCIDENCE, RISK FACTORS AND VALIDATION OF THE RABBIT SCORE FOR SERIOUS INFECTIONS IN A REAL LIFE PROSPECTIVE STUDY OF PATIENTSWITH RHEUMATOID ARTHRITIS: DATA FROM 1.549 PATIENTS. , 2019, , .		0
33	Regulatory B cells: New players in inflammatory and autoimmune rheumatic diseases. Seminars in Arthritis and Rheumatism, 2019, 48, 1133-1141.	3.4	32
34	Biologics in SAPHO syndrome: A systematic review. Seminars in Arthritis and Rheumatism, 2019, 48, 618-625.	3.4	74
35	Interstitial Lung Disease in Anti-Synthetase Syndrome. Mediterranean Journal of Rheumatology, 2019, 30, 186.	0.8	2
36	When there is a pandemic there is no time to waste: should we have hydroxychloroquine in our armoury against COVID-19 infected patients?. Mediterranean Journal of Rheumatology, 2019, 31, 94.	0.8	8

#	Article	IF	CITATIONS
37	Mediterranean Journal of Rheumatology September 2019 Issue Highlights. Mediterranean Journal of Rheumatology, 2019, 30, 139.	0.8	O
38	Anti-human Hsp60 Autoantibodies in Autoimmune and Inflammatory Rheumatic Diseases. Heat Shock Proteins, 2019, , 147-166.	0.2	0
39	The Second Greek-Israeli Symposium on Autoimmunity and Rheumatology: Success Through Synergy. Israel Medical Association Journal, 2019, 21, 292-297.	0.1	0
40	Intestinal Involvement in Systemic Sclerosis: A Clinical Review. Digestive Diseases and Sciences, 2018, 63, 834-844.	2.3	44
41	Multiple hit infection and autoimmunity: the dysbiotic microbiota–ACPA connection in rheumatoid arthritis. Current Opinion in Rheumatology, 2018, 30, 403-409.	4.3	12
42	Regulatory B and T lymphocytes in multiple sclerosis: friends or foes?. Autoimmunity Highlights, 2018, 9, 9.	3.9	32
43	Anti-Ro60 Seropositivity Determines Anti-Ro52 Epitope Mapping in Patients With Systemic Sclerosis. Frontiers in Immunology, 2018, 9, 2835.	4.8	12
44	Prevalence of comorbidities in systemic sclerosis versus rheumatoid arthritis: a comparative, multicenter, matched-cohort study. Arthritis Research and Therapy, 2018, 20, 267.	3.5	24
45	Inferior vena cava thrombosis as the initial presentation of IgG4-related retroperitoneal fibrosis: Case report and literature review. Journal of Scleroderma and Related Disorders, 2018, 3, NP1-NP6.	1.7	2
46	The Role of Flavonoids in Inhibiting Th17 Responses in Inflammatory Arthritis. Journal of Immunology Research, 2018, 2018, 1-11.	2.2	20
47	DNA Viruses in Autoimmune Rheumatic Diseases. , 2018, , 113-127.		0
48	Curcumin for the Management of Periodontitis and Early ACPA-Positive Rheumatoid Arthritis: Killing Two Birds with One Stone. Nutrients, 2018, 10, 908.	4.1	46
49	Immunotherapy of systemic sclerosis. Human Vaccines and Immunotherapeutics, 2018, 14, 1-9.	3.3	9
50	IL-35: a new immunomodulator in autoimmune rheumatic diseases. Immunologic Research, 2018, 66, 305-312.	2.9	37
51	The role of the Mediterranean diet in hyperuricemia and gout. Mediterranean Journal of Rheumatology, 2018, 29, 21-25.	0.8	19
52	Multicenter Cross-sectional Study of Patients with Rheumatoid Arthritis in Greece: Results from a cohort of 2.491 patients. Mediterranean Journal of Rheumatology, 2018, 29, 27-37.	0.8	13
53	Multiparametric autoantibody profiling of patients with systemic sclerosis in Greece. Mediterranean Journal of Rheumatology, 2018, 29, 120-126.	0.8	14
54	Enterococcus gallinarum as a component of the Autoinfectome: the gut-liver-autoimmune rheumatic disease axis is alive and kicking. Mediterranean Journal of Rheumatology, 2018, 29, 187-189.	0.8	2

#	Article	IF	CITATIONS
55	The effect of Apremilast on signal transduction and IL-10 production in CD39high regulatory B cells in patients with psoriatic arthritis. Mediterranean Journal of Rheumatology, 2018, 29, 59-61.	0.8	2
56	Human cytomegalovirus (HCMV) UL44 and UL57 specific antibody responses in anti-HCMV-positive patients with systemic sclerosis. Clinical Rheumatology, 2017, 36, 863-869.	2.2	14
57	IL-10-producing regulatory B cells (B10 cells), IL-17 + T cells and autoantibodies in systemic sclerosis. Clinical Immunology, 2017, 184, 26-32.	3.2	26
58	IL-10 producing Bregs are impaired in psoriatic arthritis and psoriasis and inversely correlate with IL-17- and IFN \hat{I}^3 -producing T cells. Clinical Immunology, 2017, 184, 33-41.	3.2	52
59	The role of platelets in autoimmunity, vasculopathy, and fibrosis: Implications for systemic sclerosis. Seminars in Arthritis and Rheumatism, 2017, 47, 409-417.	3.4	41
60	From microbiome to infectome in autoimmunity. Current Opinion in Rheumatology, 2017, 29, 369-373.	4.3	31
61	Anti-MCV antibodies predict radiographic progression in Greek patients with very early (<3Âmonths) Tj ETQq1	. 0.784314 2.2	1 rgBT /Over
62	Disease-related autoantibody profile in patients with systemic sclerosis. Autoimmunity, 2017, 50, 414-421.	2.6	73
63	Acro-osteolysis. Clinical Rheumatology, 2017, 36, 9-14.	2.2	26
64	A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease. Seminars in Arthritis and Rheumatism, 2017, 46, 625-631.	3.4	169
65	The role of Dickkopf-1 in joint remodeling and fibrosis: A link connecting spondyloarthropathies and scleroderma?. Seminars in Arthritis and Rheumatism, 2017, 46, 430-438.	3.4	16
66	Are psoriasis and psoriatic arthritis the same disease? The IL-23/IL-17 axis data. Autoimmunity Reviews, 2017, 16, 10-15.	5.8	95
67	The autoimmunity–oral microbiome connection. Oral Diseases, 2017, 23, 828-839.	3.0	111
68	The Infectious Basis of ACPA-Positive Rheumatoid Arthritis. Frontiers in Microbiology, 2017, 8, 1853.	3.5	54
69	Loss of C9orf72 function leads to autoimmunity. Annals of Translational Medicine, 2017, 5, 60-60.	1.7	3
70	Phosphodiesterase 4 Inhibitors in Immune-mediated Diseases: Mode of Action, Clinical Applications, Current and Future Perspectives. Current Medicinal Chemistry, 2017, 24, 3054-3067.	2,4	76
71	Regulatory B cells in autoimmune rheumatic diseases. Mediterranean Journal of Rheumatology, 2017, 28, 75-79.	0.8	5
72	Mediterranean Journal of Rheumatology September 2017 Highlights. Mediterranean Journal of Rheumatology, 2017, 28, 110-111.	0.8	0

#	Article	IF	CITATIONS
73	A new player in psoriatic arthritis: a JAK inhibitor. Mediterranean Journal of Rheumatology, 2017, 28, 210-211.	0.8	O
74	Increased immunoreactivity against human cytomegalovirus UL83 in systemic sclerosis. Clinical and Experimental Rheumatology, 2017, 35 Suppl 106, 31-34.	0.8	5
75	Biologic treatment for rheumatic disease: real-world big data analysis from the Greek country-wide prescription database. Clinical and Experimental Rheumatology, 2017, 35, 579-585.	0.8	14
76	Tuberculous pyomyositis: a re-emerging entity of many faces. Clinical Rheumatology, 2016, 35, 1105-1110.	2.2	18
77	Spotlight on tocilizumab and its potential in the treatment of systemic sclerosis. Drug Design, Development and Therapy, 2016, Volume 10, 2723-2728.	4.3	29
78	Infections as a cause of autoimmune rheumatic diseases. Autoimmunity Highlights, 2016, 7, 13.	3.9	26
79	Anti-hsp60 antibody responses based on Helicobacter pylori in patients with multiple sclerosis: (ir)Relevance to disease pathogenesis. Journal of Neuroimmunology, 2016, 298, 19-23.	2.3	22
80	Breg Cells Are Numerically Decreased and Functionally Impaired in Patients With Systemic Sclerosis. Arthritis and Rheumatology, 2016, 68, 494-504.	5.6	126
81	Systemic sclerosis: New evidence re-enforces the role of B cells. Autoimmunity Reviews, 2016, 15, 155-161.	5.8	102
82	The role of regulatory B cells in the homeostasis of regulatory T cells and Th17 cells in patients with systemic sclerosis. Mediterranean Journal of Rheumatology, 2016, 27, 119-120.	0.8	0
83	Safety profile of repeated rituximab cycles in unselected rheumatoid arthritis patients: a long-term, prospective real-life study. Clinical and Experimental Rheumatology, 2016, 34, 893-900.	0.8	28
84	The Role of B Cells in the Pathogenesis of Systemic Sclerosis. Israel Medical Association Journal, 2016, 18, 516-519.	0.1	6
85	Intravenous immunoglobulins (IVIG) in systemic sclerosis: a challenging yet promising future. Immunologic Research, 2015, 61, 326-337.	2.9	30
86	Early systemic sclerosis—opportunities for treatment. Clinical Rheumatology, 2015, 34, 1327-1331.	2.2	22
87	Effectiveness of Intravenous llomedin Infusion and Smoking Cessation in the Treatment of Acutely Symptomatic Buerger Disease. Angiology, 2015, 66, 114-117.	1.8	5
88	<i>Helicobacter pylori</i> and autoimmune disease: Cause or bystander. World Journal of Gastroenterology, 2014, 20, 613.	3.3	130
89	Flow Cytometric Detection of p38 MAPK Phosphorylation and Intracellular Cytokine Expression in Peripheral Blood Subpopulations from Patients with Autoimmune Rheumatic Diseases. Journal of Immunology Research, 2014, 2014, 1-13.	2.2	6
90	Anti-citrullinated peptides as autoantigens in rheumatoid arthritisâ€"relevance to treatment. Autoimmunity Reviews, 2014, 13, 1114-1120.	5.8	99

#	Article	IF	Citations
91	Scleroderma, Treatment (Current and Upcoming). , 2014, , 1044-1054.		O
92	Tracing environmental markers of autoimmunity: introducing the infectome. Immunologic Research, 2013, 56, 220-240.	2.9	35
93	High-resolution ultrasonography and 3.0ÂT magnetic resonance imaging in erosive and nodal hand osteoarthritis: high frequency of erosions in nodal osteoarthritis. Clinical Rheumatology, 2013, 32, 755-762.	2.2	33
94	Diagnostic and clinical significance of anti-centromere antibodies in primary biliary cirrhosis. Clinics and Research in Hepatology and Gastroenterology, 2013, 37, 572-585.	1.5	54
95	Enthesitis in psoriatic arthritis. Seminars in Arthritis and Rheumatism, 2013, 43, 325-334.	3.4	66
96	The Role of p38 MAPK in the Aetiopathogenesis of Psoriasis and Psoriatic Arthritis. Clinical and Developmental Immunology, 2013, 2013, 1-8.	3.3	93
97	Erosive Hand Osteoarthritis is Associated with Subclinical Atherosclerosis and Endothelial Dysfunction. International Journal of Biomedical Science, 2013, 9, 217-23.	0.1	4
98	Systemic Sclerosis: From Pathogenesis Towards Targeted Immunotherapies. Current Rheumatology Reviews, 2012, 8, 45-55.	0.8	3
99	T-Cells and B-Cells in Systemic Sclerosis. Current Rheumatology Reviews, 2010, 6, 276-282.	0.8	2
100	Editorial [Hot Topic: Systemic Sclerosis: Recent Developments are Promising (Guest Editors: Lazaros I.) Tj ETQq0	0 0 rgBT /	'Overlock 10 ⁻
101	Comparison between clinical and ultrasonographic assessment in patients with erosive osteoarthritis of the hands. Clinical Rheumatology, 2010, 29, 511-516.	2.2	32
102	Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease. Clinical Rheumatology, 2010, 29, 1167-1168.	2.2	62
103	The prevalence of rheumatic diseases in central Greece: a population survey. BMC Musculoskeletal Disorders, 2010, 11, 98.	1.9	104
104	Ultrasonographic evidence of inflammation is frequent in hands of patients with erosive osteoarthritis. Osteoarthritis and Cartilage, 2009, 17, 1283-1287.	1.3	85
105	Serum VEGF levels are related to the presence of pulmonary arterial hypertension in systemic sclerosis. BMC Pulmonary Medicine, 2009, 9, 18.	2.0	62
106	Hematogenous Spinal Infection in Central Greece. Spine, 2009, 34, E513-E518.	2.0	32
107	Co-morbidities increase the risk of serious infections in patients with rheumatoid arthritis treated with TNF $\hat{l}\pm$ inhibitors. Journal of Infection, 2008, 57, 418-420.	3.3	3
108	Anti-cyclic citrullinated peptide-2 (CCP2) autoantibodies and extra-articular manifestations in Greek patients with rheumatoid arthritis. Clinical Rheumatology, 2008, 27, 511-513.	2.2	76

#	Article	IF	CITATIONS
109	Immunological features of visceral leishmaniasis may mimic systemic lupus erythematosus. Clinical Biochemistry, 2008, 41, 65-68.	1.9	29
110	Defective Peripheral Blood Endothelial Cell Progenitors in Patients with Scleroderma and Psoriatic Arthritis. Blood, 2008, 112, 4724-4724.	1.4	0
111	The role of T cells in the pathogenesis of osteoarthritis. Arthritis and Rheumatism, 2007, 56, 409-424.	6.7	126
112	Diagnostic value of anti-cyclic citrullinated peptide antibodies in Greek patients with rheumatoid arthritis. BMC Musculoskeletal Disorders, 2007, 8, 37.	1.9	35
113	Conjunctival Surface Changes in Patients with Sjol gren's Syndrome: A Transmission Electron Microscopy Study. , 2006, 47, 541.		30
114	Mechanisms of Disease: the role of immune cells in the pathogenesis of systemic sclerosis. Nature Clinical Practice Rheumatology, 2006, 2, 679-685.	3.2	130
115	New developments in the pathogenesis of systemic sclerosis. Autoimmunity, 2005, 38, 113-116.	2.6	83
116	Identification of HLA-DQ \hat{l}_{\pm} and -DR \hat{l}_{2} Residues Associated With Susceptibility and Protection to Epithelial Ovarian Cancer. Human Immunology, 2005, 66, 554-562.	2.4	12
117	Decreased Expression of the CD3ζ Chain in T Cells Infiltrating the Synovial Membrane of Patients with Osteoarthritis. Vaccine Journal, 2004, 11, 195-202.	2.6	21
118	Is systemic sclerosis an antigen-driven T cell disease?. Arthritis and Rheumatism, 2004, 50, 1721-1733.	6.7	104
119	Identical α-chain T-cell receptor transcripts are present on T cells infiltrating coronary arteries of human cardiac allografts with chronic rejection. Cellular Immunology, 2003, 225, 75-90.	3.0	13
120	Autoantibodies in patients with systemic sclerosis and cancer: a case-control study. Journal of Rheumatology, 2003, 30, 1994-6.	2.0	16
121	Oligoclonal T Cell Expansion in the Skin of Patients with Systemic Sclerosis. Journal of Immunology, 2002, 168, 3649-3659.	0.8	185
122	APOPTOSIS IN CHRONIC REJECTION OF HUMAN CARDIAC ALLOGRAFTS1. Transplantation, 2001, 71, 1137-1146.	1.0	39
123	Differential Distribution of the Neuron-Associated Class III \hat{I}^2 -Tubulin in Neuroendocrine Lung Tumors. Archives of Pathology and Laboratory Medicine, 2000, 124, 535-544.	2.5	48
124	Is Nitric Oxide Important In Arthritis or Not?. Trends in Endocrinology and Metabolism, 1999, 10, 428-429.	7.1	0
125	Increased Levels of Alternatively Spliced Interleukin 4 (IL-4δ2) Transcripts in Peripheral Blood Mononuclear Cells from Patients with Systemic Sclerosis. Vaccine Journal, 1999, 6, 660-664.	2.6	45
126	Interleukin-12 Is Expressed by Infiltrating Macrophages and Synovial Lining Cells in Rheumatoid Arthritis and Osteoarthritis. Cellular Immunology, 1998, 188, 105-110.	3.0	68

#	Article	IF	CITATIONS
127	Immunopathogenesis of juvenile rheumatoid arthritis: Role of T cells and MHC. Immunologic Research, 1995, 14, 218-236.	2.9	12
128	T-cell antigen receptors in rheumatoid arthritis. Immunologic Research, 1994, 13, 117-138.	2.9	19
129	Southern blot analysis of HLA-DP gene polymorphisms in Caucasoid rheumatoid arthritis (RA) patients and controls. Immunogenetics, 1989, 30, 149-155.	2.4	23
130	HLA-DQw7 is a disease severity marker in patients with rheumatoid arthritis. Immunogenetics, 1989, 30, 119-122.	2.4	42
131	Pathogenetic Aspects of Systemic Sclerosis: A View Through the Prism of B Cells. Frontiers in Immunology, 0, 13 , .	4.8	59